Now showing items 1-5 of 5

    • A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. 

      Ingles Garces, AH; Ang, JE; Ameratunga, M; Chénard-Poirier, M; Dolling, D; Diamantis, N; Seeramreddi, S; Sundar, R; de Bono, J; Lopez, J; Banerji, U (2018-11)
      Background The incidence and clinical significance of electrolyte abnormalities (EAs) in phase I clinical trials are unknown. The objective of this study is to evaluate the incidence and severity of EAs, graded according ...
    • First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. 

      McLeod, R; Kumar, R; Papadatos-Pastos, D; Mateo, J; Brown, JS; Garces, AHI; Ruddle, R; Decordova, S; Jueliger, S; Ferraldeschi, R; Maiques, O; Sanz-Moreno, V; Jones, P; Traub, S; Halbert, G; Mellor, S; Swales, KE; Raynaud, FI; Garrett, MD; Banerji, U (2020-09)
      PURPOSE:AT13148 is an oral AGC kinase inhibitor, which potently inhibits ROCK and AKT kinases. In preclinical models, AT13148 has been shown to have antimetastatic and antiproliferative activity. PATIENTS AND METHODS:The ...
    • Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. 

      Ameratunga, M; Chénard-Poirier, M; Moreno Candilejo, I; Pedregal, M; Lui, A; Dolling, D; Aversa, C; Ingles Garces, A; Ang, JE; Banerji, U; Kaye, S; Gan, H; Doger, B; Moreno, V; de Bono, J; Lopez, J (2018-01)
      BACKGROUND:Although the neutrophil-lymphocyte ratio (NLR) is prognostic in many oncological settings, its significance in the immunotherapy era is unknown. Mechanistically, PD-1/PD-L1 inhibitors may alter NLR. We sought ...
    • Targeting ATR in cancer medicine. 

      Sundar, R; Brown, J; Ingles Russo, A; Yap, TA (2017-07)
      DNA damage occurs continually through various intrinsic and extrinsic mechanisms such as ultraviolet radiation, smoking, reactive oxygen species, and errors during replication. The cellular DNA damage response (DDR) comprises ...
    • Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. 

      Basu, B; Krebs, MG; Sundar, R; Wilson, RH; Spicer, J; Jones, R; Brada, M; Talbot, DC; Steele, N; Ingles Garces, AH; Brugger, W; Harrington, EA; Evans, J; Hall, E; Tovey, H; de Oliveira, FM; Carreira, S; Swales, K; Ruddle, R; Raynaud, FI; Purchase, B; Dawes, JC; Parmar, M; Turner, AJ; Tunariu, N; Banerjee, S; de Bono, JS; Banerji, U (2018-09)
      Background We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients ...